Brain

Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital

KELOWNA, BC / ACCESSWIRE / July 13, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology...

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders

Multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’sROME, July 12, 2023 (GLOBE...

Enzolytics Inc. Files Supplemental Information Report on the Sale of Biogenysis, Inc. and Virogentics, Inc to Sagaliam Acquisition Corp.

COLLEGE STATION, TX / ACCESSWIRE / July 11, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics, Inc. ("ENZC" or the "Company")...

Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria Challenges

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM Boca Raton, Florida,...

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and DurationKANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE)...

error: Content is protected !!